CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients

CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients

Summary: Chimeric antigen receptor (CAR)-T cell therapy has led to unprecedented success in treating relapsed/refractory diffuse large B cell lymphoma (DLBCL). The most common CAR-T cell products currently in the clinic for DLBCL differ in their co-stimulation moiety, containing either CD28 or 4-1BB...

Full description

Saved in:
Bibliographic Details
Main Authors: Molly S. Cook, Ellen King, Katie R. Flaherty, Khadiza Siddika, Sophie Papa, Reuben Benjamin, Anna Schurich
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Cell Reports
Subjects:
CP: Cancer
CP: Metabolism
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124725007442
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items